0001531048false00015310482023-02-272023-02-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2023

 

 

Inari Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-39293	45-2902923
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6001 Oak Canyon, Suite 100
Irvine, California				92618
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (877) 923-4747

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		NARI		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

---

Item 2.02 Results of Operations and Financial Condition.

On February 27, 2023, Inari Medical, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2022. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.		Description
99.1		Press Release of Inari Medical, Inc., dated February 27, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			INARI MEDICAL, INC.
Date:	February 27, 2023	By:	/s/ Mitchell Hill
			Mitchell Hill Chief Financial Officer

 

---

 

Exhibit 99.1

 

 

Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results

 

IRVINE, CALIFORNIA – February 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.

 

Fourth Quarter Revenue and Recent Business Highlights

 

“Crisp execution across all five of our growth drivers generated robust revenue growth in the fourth quarter,” said Drew Hykes, CEO of Inari Medical. “We are especially pleased with the milestones we achieved across several clinical studies as well as two important new product launches. Our efforts continue to drive market expansion and uptake of our devices while further distancing Inari from both existing and future competition.”

 

Fourth Quarter 2022 Financial Results

Revenue was $107.8 million for the fourth quarter of 2022, compared to $83.2 million for the fourth quarter of 2021 and $96.2 million for the prior quarter. The increase over prior periods was driven primarily by continued U.S. commercial expansion, increased adoption of our procedures, and introduction of new products.

 

Gross profit was $94.6 million for the fourth quarter of 2022, compared to $74.9 million for the same period of 2021. Gross margin was 87.8% for the fourth quarter of 2022, compared to 90.1% for the same period in the prior year. The decrease in gross margin is primarily due to the addition of new components offered under our FlowTriever system price.

 

Operating expenses for the fourth quarter of 2022 were $100.5 million, compared to $73.2 million for the fourth quarter of 2021. The increase was mainly driven by personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.

 

Net loss was $5.8 million for the fourth quarter of 2022 and net loss per share was $0.11 on a weighted-average basic and diluted share count of 53.6 million, compared to a net income of $1.1 million and a net income per share of $0.02 on a weighted-average basic share count of 50.2 million and $0.02 on a weighted average diluted share count of 55.6 million, in the same period of the prior year.

 

---

 

 

Full Year 2022 Financial Results

Revenue was $383.5 million for the year ended December 31, 2022, compared to $277.0 million in the prior year. The increase over prior periods was driven primarily by continued U.S. commercial expansion, increased adoption of our procedures, and introduction of new products.

 

Gross profit was $339.0 million for the full year of 2022, compared to $252.2 million for the prior year. Gross margin was 88.4% for the full year of 2022, compared to 91.1% for the prior year. The decrease in gross margin is primarily due to the addition of new components offered under our FlowTriever system price and a decrease in operating leverage due to the expanded footprint of our manufacturing operations.

 

Operating expenses for the full year of 2022 were $367.1 million, compared to $241.4 million for the prior year. The increase was mainly driven by personnel-related expenses as we increased headcount to fund the expansion of the commercial, research and development, clinical, and support organizations.

 

Net loss was $29.3 million for the full year of 2022 and net loss per share was $0.55 on a weighted-average basic and diluted share count of 52.8 million, compared to a net income of $9.8 million and net income per share of $0.20 on a weighted-average basic share count of 49.8 million and $0.18 on a weighted-average diluted share count of 55.6 million, in the prior year.

 

Full-Year 2023 Revenue Guidance

For the full year 2023, we are reaffirming our revenue guidance range of $470 million to $480 million.

 

Webcast and Conference Call Information

Inari Medical will host a conference call to discuss the fourth quarter and full year 2022 financial results after market close on Monday, February 27, 2023 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live by dialing 844-825-9789 for domestic callers or 412-317-5180 for international callers, using conference ID: 10175548. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com.

 

About Inari Medical, Inc.

Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

 

Forward Looking Statements

Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include estimated full year 2023 revenue and are based on Inari’s current expectations, forecasts, and assumptions, are subject to

 

---

 

inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2022, and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.

 

Investor Contact:

ICR Westwicke

Caroline Corner

Phone +1-415-202-5678

caroline.corner@westwicke.com

 

---

 

Inari Medical, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except share and per share data)

 

		Three Months Ended December 31,								Years Ended December 31,
		2022				2021				2022				2021
Revenue		$	107,771			$	83,218			$	383,471			$	276,984
Cost of goods sold			13,128				8,280				44,506				24,757
Gross profit			94,643				74,938				338,965				252,227
Operating expenses
Research and development			20,412				18,726				74,221				51,018
Selling, general and administrative			80,122				54,466				292,843				190,365
Total operating expenses			100,534				73,192				367,064				241,383
(Loss) income from operations			(5,891	)			1,746				(28,099	)			10,844
Other income (expense)
Interest income			970				24				1,852				154
Interest expense			(74	)			(75	)			(294	)			(295	)
Change in fair value of warrant liabilities			—				—				—				—
Other income (expense)			187				(14	)			356				(18	)
Total other income (expense)			1,083				(65	)			1,914				(159	)
(Loss) income before income taxes			(4,808	)			1,681				(26,185	)			10,685
Provision for income taxes			990				574				3,082				845
Net (loss) income		$	(5,798	)		$	1,107			$	(29,267	)		$	9,840
Other comprehensive income (loss)
Foreign currency translation adjustments			222				(110	)			(592	)			(379	)
Unrealized gain (loss) on available-for-sale debt securities			1,572				(46	)			1,843				(27	)
Total other comprehensive income (loss)			1,794				(156	)			1,251				(406	)
Comprehensive (loss) income		$	(4,004	)		$	951			$	(28,016	)		$	9,434
Net (loss) income per share
Basic		$	(0.11	)		$	0.02			$	(0.55	)		$	0.20
Diluted		$	(0.11	)		$	0.02			$	(0.55	)		$	0.18
Weighted average common shares used to compute net (loss) income per share
Basic			53,610,347				50,229,356				52,837,674				49,815,914
Diluted			53,610,347				55,627,807				52,837,674				55,594,159

 

 

 

---

 

Inari Medical, Inc.

Consolidated Balance Sheets

(in thousands, except share data)

 

		December 31, 2022				December 31, 2021
Assets
Current assets
Cash and cash equivalents		$	60,222			$	92,752
Short-term investments in debt securities			266,179				83,348
Accounts receivable, net			58,611				42,351
Inventories, net			32,581				21,053
Prepaid expenses and other current assets			5,312				5,694
Total current assets			422,905				245,198
Property and equipment, net			21,655				16,471
Operating lease right-of-use assets			50,703				44,909
Deposits and other assets			8,889				981
Long-term investments in debt securities			—				3,983
Total assets		$	504,152			$	311,542
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable		$	7,659			$	6,541
Payroll-related accruals			38,955				24,433
Accrued expenses and other current liabilities			8,249				10,737
Operating lease liabilities, current portion			1,311				802
Total current liabilities			56,174				42,513
Operating lease liabilities, noncurrent portion			30,976				28,404
Other long-term liability			—				1,416
Total liabilities			87,150				72,333
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021			—				—
Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2022 and 2021; 54,021,656 and 50,313,452 shares issued and outstanding as of December 31, 2022 and 2021, respectively			54				50
Additional paid in capital			462,949				257,144
Accumulated other comprehensive income (loss)			849				(402	)
Accumulated deficit			(46,850	)			(17,583	)
Total stockholders' equity			417,002				239,209
Total liabilities and stockholders' equity		$	504,152			$	311,542

 

 

---